| Popis: |
Patients with combat related posttraumatic stress disorder (PTSD) with psychotic features frequently fail to respond to antidepressants. We have previously shown that these patients improved significantly after monotherapy with atypical antipsychotics, olanzapine or risperidone. We investigated the clinical outcome of another atypical antipsychotic, quetiapine, in a large group of well characterized male war veterans with combat related PTSD with psychotic features, in a naturalistic study. Male war veterans (N=53) with DSM-IV-diagnosed PTSD with psychotic symptoms, completed 8-weeks of inpatient treatment (from December 2002 to January 2005) with quetiapine (25-400 mg/day). The reductions from baseline to endpoint (8 weeks) in the total and subscale scores on the Clinician-Administered PTSD Scale, and the increase in five-point Clinical Global Impression-Improvement Scale (CGI-I) were the primary, and in Positive and Negative Syndrome Scale (PANSS) the secondary outcome measures. CGI-Severity of Illness scale (CGI-S) was used to assess the clinical improvement. Drug-Induced Extrapyramidal Symptoms scale recorded adverse effects. Two, 6 and 8 weeks of treatment with quetiapine significantly reduced (p |
